Alzinova announced FDA approval of its Investigational New Drug application for ALZ-101, a novel vaccine targeting toxic amyloid-beta oligomers implicated in Alzheimer’s disease. Following promising Phase Ib safety and immunogenicity data, the Phase II clinical trial will evaluate ALZ-101 in a larger patient cohort in the US, aiming to confirm therapeutic potential by stimulating antibody production against pathological amyloid species. This milestone marks significant progress toward an active immunization strategy to modify the course of Alzheimer's.